Hutchmed (China) Limited

HCM

Equity

ISIN US44842L1035 / Valor 30165904

NASDAQ (2024-11-21)

USD 17.68-1.56%

Hutchmed (China) Limited
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Hutchmed (China) Limited is a biopharmaceutical company that focuses on research and development in the areas of cancer and immunological diseases. The company's core philosophy involves utilizing multiple modalities and mechanisms to develop highly selective, potent, and well-tolerated cancer therapies. Hutchmed is dedicated to improving drug exposure and reducing off-target toxicities through a science-focused approach.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

Hutchmed (China) Limited reported a consolidated oncology product revenue of $168.7 million for the first half of 2024, driven by a 59% growth in oncology product revenue compared to the same period in 2023. This growth was primarily fueled by the strong performance of their oncology products in the market.

FRUZAQLA® Sales

FRUZAQLA® (fruquintinib ex-China) achieved US in-market sales of $130.5 million in the first half of 2024. This strong performance reflects the rapid uptake by US patients and the fulfillment of sales channel inventory requirements since its launch in November 2023.

Net Income

Hutchmed (China) Limited reported a net income of $25.8 million for the first half of 2024. This positive financial result underscores the company's ability to generate profit while continuing to invest in key R&D projects and enhancing commercial efficiency.

Cash Balance

As of June 30, 2024, Hutchmed (China) Limited maintained a substantial cash balance of $802.5 million. This strong cash position supports the company's ongoing growth initiatives and strategic investments in research and development.

Oncology In-Market Sales

Oncology in-market sales for Hutchmed (China) Limited increased by 140% to $243.3 million in the first half of 2024, compared to $101.3 million in the same period of 2023. This significant growth was driven by the strong performance of key products such as FRUZAQLA®, ELUNATE®, SULANDA®, and ORPATHYS®.

Summarized from source with an LLMView Source

Key figures

-2.64%1Y

-42.4%3Y

-25.0%5Y

Performance

57.7%1Y

74.6%3Y

67.8%5Y

Volatility